Shares shifted sharply higher as Novo Nordisk posted a third-quarter earnings beat that exceeded Wall Street targets by a wide margin, giving investors their clearest sign yet that the Danish drugmaker's turnaround has traction. Q3 revenue hit $11.90 billion, above the $11.39 billion forecast.
Adjusted earnings reached $0.87 per share, topping analysts' $0.81 estimate. The stock climbed roughly 5–6%, landing within the ±6.9% implied move the options market had priced in — a solid beat, but not a blowout reaction.
The Pill Is Now Novo's Growth Engine — And That Cuts Both Ways
The oral version of Wegovy brought in DKK 5.39 billion (~$810 million) in Q3, up 53% from the prior quarter and well above the DKK 4.62 billion consensus.
Total pill prescriptions reached about 3.6 million in Q3, with cumulative scripts exceeding 8 million since the January launch — the strongest-ever GLP-1 volume launch in the U.S. But here's the tension: U.S. injectable Wegovy sales fell 13%, while combined pill-and-injection sales rose 21% excluding currency moves. The pill is clearly cannibalizing the injection, and management hasn't clarified how much growth comes from genuinely new patients versus existing users switching formats.
A Third Guidance Raise Signals Real Momentum — From a Low Bar
Novo raised its 2026 outlook for the third time this year, lifting adjusted sales and operating-profit growth guidance to -2% to +2% at constant exchange rates, up from flat to a 6% decline. That's encouraging progress, but even the best-case scenario is only 2% growth — hardly blockbuster for a company that once grew in the double digits. Results came in roughly 8% above sales expectations and 12% above adjusted operating-profit expectations , so execution is outrunning guidance, which could set up further upgrades.
Wall Street Isn't Ready to Call the All-Clear
Citi maintained a neutral rating, citing uncertainty over weight-loss drug pricing and a lack of a clear Wegovy successor in the pipeline.
The stock fell nearly 8% in a single session in September after Novo failed to reassure investors about its post-Wegovy growth strategy.
Planned U.S. price cuts and intensifying Eli Lilly competition remain key investor concerns. At a trailing price-to-earnings ratio of roughly 10×, shares are priced for skepticism — but that also means any sustained acceleration could reward patient holders disproportionately.
The Bottom Line: Novo proved the pill works commercially. The unresolved question is whether one product's momentum can outrun pricing headwinds and a bare pipeline before the market's patience runs out.